Viking Global Investors led the Novo-backed company's latest round, which will be used to commercialise its ablation-based BPH treatment.
Procept BioRobotics, a US-based surgical robotics technology developer backed by pharmaceutical company Novo, secured $118m yesterday in a funding round led by investment firm Viking Global Investors.
Hedge fund sponsor Perceptive Advisors also took part in the round alongside existing backers including investment management firm CPMG.
Procept will use the proceeds to support the international commercialisation of its lead product, an aquablation system that uses water jet therapy to treat benign prostatic hyperplasia (BPH), a condition in which the prostate…
